DB Fitzpatrick & Co Inc Raises Stock Holdings in Thermo Fisher Scientific Inc. $TMO

Key Points

• DB Fitzpatrick & Co Inc increased its holdings in Thermo Fisher Scientific by 20% to a total of 3,898 shares, worth approximately $1.58 million, making it the firm's 16th largest holding.
• Equity analysts are optimistic about Thermo Fisher Scientific, with 16 ratings for Buy and an average price target of $588.35, reflecting a positive sentiment in the market.
• CEO Marc N. Casper recently sold 400 shares for $200,200, reducing his ownership by 0.35%, while insiders have sold a total of 30,066 shares valued at over $14 million in the last 90 days.

DB Fitzpatrick & Co Inc raised its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 20.0% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 3,898 shares of the medical research company's stock after purchasing an additional 649 shares during the period. Thermo Fisher Scientific comprises approximately 1.4% of DB Fitzpatrick & Co Inc's holdings, making the stock its 16th largest holding. DB Fitzpatrick & Co Inc's holdings in Thermo Fisher Scientific were worth $1,580,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. Bernard Wealth Management Corp. acquired a new stake in Thermo Fisher Scientific during the fourth quarter valued at approximately $25,000. CBIZ Investment Advisory Services LLC lifted its stake in Thermo Fisher Scientific by 137.5% during the first quarter. CBIZ Investment Advisory Services LLC now owns 57 shares of the medical research company's stock worth $28,000 after purchasing an additional 33 shares during the last quarter. Ameriflex Group Inc. bought a new stake in Thermo Fisher Scientific during the fourth quarter valued at $30,000. Anderson Financial Strategies LLC acquired a new stake in shares of Thermo Fisher Scientific during the first quarter worth $30,000. Finally, Keystone Global Partners LLC acquired a new position in shares of Thermo Fisher Scientific in the 1st quarter valued at about $31,000. 89.23% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on TMO shares. Royal Bank Of Canada set a $561.00 target price on shares of Thermo Fisher Scientific and gave the stock an "outperform" rating in a report on Tuesday, September 2nd. UBS Group boosted their price objective on Thermo Fisher Scientific from $460.00 to $500.00 and gave the company a "neutral" rating in a research report on Thursday, July 24th. Raymond James Financial reaffirmed an "outperform" rating and issued a $535.00 target price (up from $525.00) on shares of Thermo Fisher Scientific in a research report on Thursday, July 24th. Barclays upgraded shares of Thermo Fisher Scientific from an "equal weight" rating to an "overweight" rating and upped their price target for the stock from $490.00 to $550.00 in a research report on Thursday, September 11th. Finally, Scotiabank upgraded shares of Thermo Fisher Scientific from a "sector perform" rating to a "sector outperform" rating and set a $590.00 price objective on the stock in a research report on Friday, July 11th. Sixteen investment analysts have rated the stock with a Buy rating and five have given a Hold rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $588.35.

Insider Transactions at Thermo Fisher Scientific

In other news, CEO Marc N. Casper sold 400 shares of the company's stock in a transaction on Friday, September 5th. The stock was sold at an average price of $500.50, for a total value of $200,200.00. Following the completion of the sale, the chief executive officer owned 113,762 shares in the company, valued at $56,937,881. This represents a 0.35% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CAO Joseph R. Holmes sold 385 shares of Thermo Fisher Scientific stock in a transaction dated Friday, August 29th. The stock was sold at an average price of $492.63, for a total value of $189,662.55. Following the transaction, the chief accounting officer directly owned 2,319 shares in the company, valued at approximately $1,142,408.97. The trade was a 14.24% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 30,066 shares of company stock valued at $14,182,963. Corporate insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Stock Performance

TMO stock opened at $469.41 on Wednesday. The company has a 50-day simple moving average of $474.01 and a 200 day simple moving average of $448.70. The company has a market capitalization of $177.25 billion, a P/E ratio of 27.15, a PEG ratio of 2.54 and a beta of 0.75. The company has a quick ratio of 1.50, a current ratio of 1.93 and a debt-to-equity ratio of 0.65. Thermo Fisher Scientific Inc. has a fifty-two week low of $385.46 and a fifty-two week high of $623.77.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings results on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, topping analysts' consensus estimates of $5.22 by $0.14. The company had revenue of $10.86 billion for the quarter, compared to the consensus estimate of $10.68 billion. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. Thermo Fisher Scientific's revenue was up 2.9% on a year-over-year basis. During the same period in the previous year, the firm earned $5.37 EPS. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Sell-side analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, October 15th. Stockholders of record on Monday, September 15th will be given a dividend of $0.43 per share. The ex-dividend date is Monday, September 15th. This represents a $1.72 annualized dividend and a dividend yield of 0.4%. Thermo Fisher Scientific's dividend payout ratio (DPR) is 9.95%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.